Antibiotics only
PreclinicalSmall molecule
Antibiotics only is one of 26 small molecule programs targeting Appendicitis. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Appendicitis
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Flagyl
DDePuy Orthopaedics
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Levaquin
WWim Janssens
Approved
Merrem
BB. Braun Medical Inc.
Approved
Monurol
MMeitheal
Approved
Ketalar
AAultman Health Foundation
Approved
Betadine
BBecton, Dickinson and Company
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antibiotics only. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- GGeorge Washington University